Trial · NCT02068495
Adverse events64
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 64
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | Nervous system disorders | Candesartan Cilexetil/Amlodipine | 15 | 3,300 | |
| other | Hepatic function abnormal | Hepatobiliary disorders | Candesartan Cilexetil/Amlodipine | 18 | 3,300 | |
| other | Blood creatinine increased | Investigations | Candesartan Cilexetil/Amlodipine | 12 | 3,300 | |
| other | Blood pressure decreased | Investigations | Candesartan Cilexetil/Amlodipine | 21 | 3,300 | |
| other | Blood urea increased | Investigations | Candesartan Cilexetil/Amlodipine | 17 | 3,300 | |
| other | Gamma-glutamyltransferase increased | Investigations | Candesartan Cilexetil/Amlodipine | 14 | 3,300 | |
| serious | Peritonitis | Infections and infestations | Candesartan Cilexetil/Amlodipine | 2 | 3,300 | |
| serious | Pneumonia | Infections and infestations | Candesartan Cilexetil/Amlodipine | 6 | 3,300 | |
| serious | Pyelonephritis | Infections and infestations | Candesartan Cilexetil/Amlodipine | 1 | 3,300 | |
| serious | Urinary tract infection | Infections and infestations | Candesartan Cilexetil/Amlodipine | 2 | 3,300 | |
| serious | Infectious pleural effusion | Infections and infestations | Candesartan Cilexetil/Amlodipine | 1 | 3,300 | |
| serious | Appendicitis | Infections and infestations | Candesartan Cilexetil/Amlodipine | 1 | 3,300 | |
| serious | Bile duct cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Candesartan Cilexetil/Amlodipine | 1 | 3,300 | |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Candesartan Cilexetil/Amlodipine | 2 | 3,300 | |
| serious | Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Candesartan Cilexetil/Amlodipine | 2 | 3,300 | |
| serious | Plasma cell myeloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Candesartan Cilexetil/Amlodipine | 1 | 3,300 | |
| serious | Liver carcinoma ruptured | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Candesartan Cilexetil/Amlodipine | 1 | 3,300 | |
| serious | Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Candesartan Cilexetil/Amlodipine | 2 | 3,300 | |
| serious | Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Candesartan Cilexetil/Amlodipine | 1 | 3,300 | |
| serious | Anaemia | Blood and lymphatic system disorders | Candesartan Cilexetil/Amlodipine | 1 | 3,300 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02068495/events